Central to the exposé is Brook Jackson, who, for two weeks,
Shares of the German biotechnology company BioNTech that
took a dramatic 20-percent plunge on Friday, in wake of a damning whistleblower report.
The price of BioNTech shares traded on the US NASDAQ exchange briefly fell by some $60 and stood at around $216 at the time of writing.
Some analysts have immediately tied the dramatic fall – which amounted to more than 20% – to the publication of an explosive report on the trial of the Pfizer-BioNTech Covid jab. Published in the British Medical Journal (BMJ) on Tuesday, the report cites a former contractor and claims to expose a staggering level of incompetence